- Open Access
PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma
Cell & Bioscience volume 11, Article number: 185 (2021)
Background and aim
The proline rich mitotic checkpoint control factor (PRCC) is involved in the splicing process of pre-mRNA. This study aims to elucidate PRCC molecular function, regulatory mechanism and diagnostic value in hepatocellular carcinoma (HCC).
The tissue microarray and serum samples from HCC patients were used to investigate the clinical value of PRCC. The biological function and molecular mechanism of PRCC were demonstrated by cell biology, biochemical and animal experiments. The relationship between PRCC and intratumoral heterogeneity (ITH) was analyzed by bioinformatics.
PRCC was highly expressed in HCC tissues and related to the poor prognosis of HCC patients, its contents were elevated in the preoperative sera of HCC patients. PRCC exhibited high application potential as a substitute or adjuvant of alpha-fetoprotein (AFP) for clinical diagnosis of HCC. It had no significant effect on the proliferation of cancer cells, but could inhibit spheroid formation and metastasis of HCC cells in vitro and in vivo. The high ectopic expression of PRCC made cancer cells insensitive to DNA damage, and enhanced the heterogeneity of HCC cells by inhibiting the JNK/ATM/ATR/ATF2 axis. The HCC patients with high PRCC expression had high ITH, which corresponded to a short overall survival in patients.
PRCC has high application potential as a substitute or adjuvant of AFP for clinical diagnosis of HCC. The high ectopic expression of PRCC not only caused HCC cells to resist to cell death induced by DNA damage, but also endowed cancer cells with numerous DNA mutations to become increasingly heterogeneous, finally leading to a poor prognosis in HCC patients. These data suggested PRCC could be a promising therapeutic target in HCC patients.
Hepatocellular carcinoma (HCC) is currently one of the most common malignant tumors, its morbidity and mortality have remained high for a long time . Metastasis and recurrence after surgery, insensitivity to radiotherapy and chemotherapy, and high heterogeneity of HCC have become the bottleneck to improve the long-term efficacy after treatment [2, 3]. The sensitivity and specificity of existing diagnostic markers and therapeutic targets for HCC do not meet the clinical requirements . Therefore, further research in molecular mechanisms of HCC occurrence and development is of great significance for clinical diagnosis and treatment of HCC.
PRCC (Gene ID: 5546) is a protein element involved in the pre-mRNA splicing process. The fusion protein formed by PRCC and transcription factor binding to IGHM enhancer 3 (TFE3) increases the activity of TFE3 and promotes the transcription of serpin family E member 1 (SERPINE1) . The recruitment of phosphorylated PRCC to precursor mRNA activates the human spliceosome B complex . PRCC participates in the formation of spliceosome [7, 8]. In addition, PRCC is involved in checkpoint control, colony formation, cell apoptosis, and can interact with mitotic arrest deficient 2-like protein 2 (MAD2B) and transfer it into nucleus to perform function .
There is no research on the role and mechanism of PRCC in HCC up to now. This study found that PRCC was highly expressed in HCC cells and tissues, and its contents were elevated in the preoperative sera of most HCC patients. Research on the clinical diagnostic significance of PRCC and its molecular mechanism in HCC will help to find new diagnostic indicators and treatment targets for HCC.
Materials and methods
Sample collection and PRCC detection
This study was approved by the Committee on Ethics of Medicine, Navy Military Medical University (Shanghai, China). All patients signed informed consents. Sixty-six pairs of human HCC and adjacent tissue samples were collected and made into HCC tissue microarray. PRCC expression in HCC and adjacent tissues was detected by immunohistochemistry (IHC). AlgorithmS program of ImageScope software (Aperio) was used to calculate the histochemical score. The median of the scores was selected to distinguish between high and low levels of PRCC. The correlations between PRCC and clinicopathological characteristics and survival were analyzed.
The preoperative serum samples from 105 HCC patients and 24 healthy volunteers were collected and stored at −80 ℃. The enzyme-linked immunosorbent assay (ELISA) detection kit (YX-H86033, Shanghai Sinobestbio Biotechnology Co., Ltd, Shanghai, China) was used to detect the concentration of PRCC in sera. All procedures were followed the kit instructions. ROC (receiver operating characteristics) analysis was performed to determine whether the concentration of PRCC in sera can be used as a diagnostic index for HCC.
Cell lines and cell culture
The human HCC cell lines, including Hep3B, Huh7, QGY-7701, LM3 and immortalized liver cells WRL-68, were all provided by the Chinese Academy of Sciences Stem Cell Bank. The cells were cultured in DMEM with 10% FBS (Gibco, USA) and incubated in a CO2 incubator at 37 °C.
Overexpression and knockdown of PRCC
The coding sequence (CDS) of PRCC (NM_005973.5) was synthesized and constructed into pLV-EF1α-EGFP-N plasmid (Inovogen, VL3311) to generate the PRCC overexpression vector. The short hairpin RNA 1 (shRNA1) and shRNA2 sequences were designed and constructed into pLKO.1 plasmid (Addgene, Plasmid #10878) to generate the PRCC knockdown vectors. The shRNA1 and shRNA2 sequences were as follows: 5’-ccgggctggtgcttattatcaggatctcgagatcctgataataagcaccagctttttg-3’ (shRNA1); 5’-ccggacaccagatcacatatcttatctcgagataagatatgt gatctggtgttttttg-3’ (shRNA2). The overexpression and knockdown vectors were packaged into lentiviruses which were used to infect the target cells. The cell sublines with overexpression or knockdown of PRCC were confirmed by Western Blot.
Quantitative reverse transcription PCR (RT-qPCR)
Total RNA was extracted with Trizol reagent (Invitrogen, USA), and then the transcriptional levels of genes were tested by RT-qPCR. The primers involved were shown in Additional file 1: Table S1.
Animal experiments were approved by the Committee on Ethics of Medicine, Navy Military Medical University. All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals.” Eighteen purebred 6-weeks-old Balb/c male nude mice were divided into three groups: blank control group (Hep3B), negative control group (Hep3B-EGFP) and PRCC overexpression group (Hep3B-PRCC OE). Each group contained 6 mice, and the corresponding cell sublines were injected into the tail vein (8 × 105 cells/150 μl per mouse). Thirty days later, mice were sacrificed painlessly, and dissected to observe the tumor formation in lungs, livers and kidneys. HE staining was performed.
Spheroid assay and immunofluorescence (IF)
One thousand cells per 150 μl (diluted in DMEM) were mixed with 150 μl Matrigel and spread evenly in a 24-well plate. After cultured for one week, the cell spheres appeared. The cell spheres were collected and the immunofluorescence procedure was carried out. The antibodies used were shown in Additional file 1: Table S2.
Inhibition of cell proliferation and cell cycle
After incubated for 24 h in 96-well plates, cells were treated with ultraviolet (UV) irradiation with a dose of 5 J/m2 [Dose (mJ/cm2) = Exposure time (s) × Output intensity (mW/cm2)] and cultured for another 24 h, or cells were treated with 30 μM Cisplatin (DDP) for 24 h. Then CCK8 assay was carried out, and the inhibition rate was calculated.
After cultured for 24 h in petri dishes, cells were treated with UV irradiation with a dose of 5 J/m2 and cultured for another 24 h, or cells were treated with 30 μM DDP for 24 h. The cells were collected and the flow cytometry was used for cell cycle detection.
The cells were collected and lysed with RIPA lysis buffer (1% PMSF, 1% phosphatase inhibitor and 1% protease inhibitor were added). The Western blot procedure was carried out as usual. The antibodies involved were shown in Additional file 1: Table S2.
Analysis of intratumoral heterogeneity (ITH)
The single nucleotide variation (SNV) files based on whole-exome sequencing (WES) of 365 patients with HCC were downloaded from the Cancer Genome Atlas (TCGA)—liver and intrahepatic bile ducts (LIHC) project of the website (https://portal.gdc.cancer.gov/). Mutant-allele tumor heterogeneity (MATH) is a simple, quantitative, and universally applicable method for assessing ITH. R program was used to calculate MATH . The calculation program was described in the Additional file 1.
Based on the results of RNA Seq V2 RSEM in TCGA database of liver cancer, the samples were divided into high and low expression groups of PRCC. Then the differences of ITH between the two groups were analyzed. The relationship between ITH and overall survival was analyzed with follow-up data.
Graphpad Prism 5 and SPSS 19.0 software were used for statistical analysis. Data were expressed as‾x ± SD (standard deviation). Analysis of Variance (ANOVA) was used for comparison between groups. The gray value was analyzed by Image-Pro Plus 6.0 software. The statistical graphs were made with Graphpad Prism 5 and Adobe Illustrator CS5 software. P < 0.05 indicated that the difference was statistically significant.
PRCC is upregulated in HCC tissues and sera of patients and associated with poor prognosis
The expression of PRCC in 12 pairs of HCC and adjacent normal tissues was detected by Western blot. The results showed that the protein level of PRCC in HCC tissues was significantly higher than that in adjacent normal tissues in 10 pairs of clinical samples, and was slightly lower in only one pair of samples, the remaining 1 pair of HCC tissue and adjacent tissue were equivalent expression for PRCC (Fig. 1a). IHC was performed on HCC tissue microarray including clinical samples from 66 HCC patients, and found that PRCC expression was elevated in HCC tissues compared with the adjacent tissues in 43 (65.15%) pairs of samples, and was reduced in 13 (19.70%) pairs of samples, there was no significant difference in its expression in the remaining 10 (15.15%) pairs of samples (Fig. 1b). ImageScope software (Aperio) was used to score the expression of PRCC in HCC tissues, and the median value of the scores was used to distinguish the groups with high and low levels of PRCC. Combined with analysis of the patients' clinicopathological characteristics and follow-up data, it was found that PRCC was significantly related to AFP level, portal vein tumor thrombus (PVTT) and TNM stage (Table 1). The results of survival analysis showed that the overall survival (OS) of HCC patients with high level of PRCC was significantly shorter than that of patients with low level of PRCC. The protein level of PRCC had no significant correlation with the progression-free survival (PFS) (Fig. 1c, d). The result was consistent with the analysis of the TCGA database (Additional file 1: Fig. S1).
In addition, ELISA was used to detect PRCC concentration in sera of 105 HCC patients and 24 healthy volunteers. The results showed that PRCC concentration in sera of HCC patients was significantly higher than that of healthy volunteers, and the difference was statistically significant (P < 0.001) (Fig. 1e). Combined with the clinical diagnosis results, ROC analysis was performed through SPSS 19.0 software. The cutoff value of PRCC concentration in sera was 0.99 μg/ml, which meant that the patient would be more likely to develop HCC if his cutoff value was higher than 0.99 μg/ml. The area under the ROC curve (AUC) of PRCC was 0.869 (P < 0.05). The sensitivity of PRCC as a diagnostic index for HCC was 84%, and the specificity was 83% (Fig. 1f). Compared with AFP (based on randomly collected clinical data, the sensitivity of AFP for diagnosis of HCC was 59.05%, 62/105), PRCC had significant advantages in the sensitivity for HCC diagnosis. Therefore, PRCC was a potential substitute or adjuvant of AFP for clinical diagnosis of HCC. The above results indicated that the protein level of PRCC was generally high in HCC, which was related to a poor prognosis of HCC patients. It could be detected in sera and had high sensitivity as a diagnostic index for HCC.
PRCC has no significant effect on the proliferation of HCC cells
The mRNA and protein levels of PRCC in HCC cell lines were detected by RT-qPCR and Western blot, respectively. The results showed that the expression of PRCC in HCC cell lines (except HepG2) was generally higher than that in immortalized liver cells WRL-68 (Fig. 2a, b). Because HepG2 cells grew in colony state and were inconvenient for morphological observation, they were not selected as experimental cells. Instead, Hep3B and Huh7 cells with relatively low PRCC expression were selected to prepare the overexpressed cell sublines. QGY-7701 and LM3 cells with relatively high PRCC expression were selected to prepare the knockdown cell sublines. The exogenous PRCC-EGFP was stably expressed in the Hep3B (Hep3B-PRCC OE) and Huh7 (Huh7-PRCC OE) cell sublines. The transcriptional expression of PRCC was stably knocked down by two different shRNA vectors in the QGY-7701 (QGY-7701-PRCC KD) and LM3 (LM3-PRCC KD) cell sublines. Fluorescence microscopy showed that PRCC located in cell nuclei (Fig. 2c). The overexpression and knockdown of PRCC in cells was also confirmed by Western blot (Fig. 2d). The results of cell counting kit-8 (CCK8) assay showed that PRCC had no significant effect on the proliferation of HCC cells (Fig. 2e and Additional file 1: Fig. S2a). However, the results of colony formation assay showed that PRCC could inhibit the colony forming ability of HCC cells (Fig. 2f and Additional file 1: Fig. S2b).
PRCC suppresses HCC cell spheroid formation
A three-dimensional spheroid assay was used to detect the spheroidizing ability of HCC cells. In the PRCC overexpression group, the ability of cancer cells to form spheroids was inhibited. Knockdown of PRCC promoted the formation of spheroids (Fig. 3a). The stem cell markers in Hep3B cell spheres were observed by immunofluorescence staining, and it was found that the four stem cell markers including EpCAM, β-catenin, CD44 and CD133 were all positive (Fig. 3b), demonstrating that the spheroid cells had the characteristics of stem cells. In summary, the high expression of PRCC had an inhibitory effect on cell spheroid formation.
PRCC inhibits HCC cell metastasis in vitro and in vivo
The overexpression of PRCC significantly inhibited cell migration and invasion of Hep3B and Huh7 cells, while the knockdown of PRCC in QGY-7701 and LM3 cells exhibited the opposite results (Fig. 4a, b and Additional file 1: Fig. S2c, d). The transcription of E-cadherin was significantly up-regulated (Fig. 4c). Western blot exhibited consistent results (Fig. 4d). A nude mouse model was used by cell injection through tail vein to verify the effect of PRCC on metastasis and tumorigenicity of HCC cells, and the results showed no significant difference in mouse body weight among the Hep3B, Hep3B-EGFP and Hep3B-PRCC OE groups, but the size and numbers of tumors in mouse lung tissues in the Hep3B group and Hep3B-EGFP group were significantly higher than that in the Hep3B-PRCC OE group, and the difference was statistically significant (P < 0.05) (Fig. 4e–g). The liver and kidney tissues in the three groups were not found to have metastases (Fig. 4g). The above results indicated that the high expression of PRCC could inhibit the metastasis and tumor formation of HCC cells in vitro and in vivo.
High expression of PRCC makes cancer cells insensitive to DNA damage
Clinical data analysis showed that PRCC played a "bad" role in the occurrence and development of HCC (Fig. 1). However, PRCC did not show any effect of increasing the malignancy of HCC cells in cytology experiments, but instead inhibited the metastasis and spheroid formation of HCC cells (Figs. 3 and 4). The analysis of co-expression data from TCGA database (http://www.cbioportal.org/results/coexpression) indicated that the expression of PRCC was negatively correlated with the key factors involved in the DNA damage repair process, such as ATM/ATR and HIPK2, and was positively correlated with CDC25C and CDK1 (Fig. 5a) [36, 37]. It could be speculated that PRCC may promote the occurrence and poor prognosis of HCC by affecting DNA damage repair pathways.
Therefore, UV irradiation was used to treat Hep3B and QGY-7701 cells to make DNA damage. The results showed that the proliferation of HCC cells was significantly inhibited by UV irradiation, and the inhibition rate was dose-dependent. The inhibition rate of UV irradiation in PRCC overexpression cells was significantly lower than that in the control group (Fig. 5b). After UV irradiation, the cell cycle distribution in the PRCC overexpression cells changed significantly, the cell ratio in G2/M phase decreased and the cell ratio in S phase increased compared with the control group (Fig. 5c). In addition, the sensitivity of the PRCC overexpression cells to the DNA damage chemotherapeutic drug DDP was significantly reduced (Fig. 5d). After treatment with 30 μM of DDP for 24 h, the cell cycle distribution in the PRCC overexpression cells also changed compared with the control group, the cell ratio in G2/M phase was also decreased (Fig. 5e). The results showed that once DNA was damaged, HCC cells with high protein level of PRCC could not respond as the way normal cells did, they could neither be induced directly into the apoptotic process (indicated by the reduced inhibition rate), nor block the cell cycle to complete DNA repair. Instead, the cells with damaged DNA continued to proliferate (indicated by cell cycle distribution changes) and passed the mutated DNA to daughter cells. The results indicated that the high expression of PRCC affected the response and reduced the sensitivity of cells to DNA damage, and indirectly promoted the progression of HCC.
PRCC reduces the sensitivity of HCC cells to DNA damage by inhibiting the JNK/ATM/ATR/ATF2 axis
The analysis of TCGA co-expression data showed that PRCC expression was negatively correlated with ATF2 expression (Fig. 5a). ATF2 is a phosphorylation-dependent transcription factor and a substrate of JNK and P38 [11,12,13,14]. JNK signaling pathway can be activated by cytokines, growth factors, stress and other factors. The overexpression of PRCC resulted in a significant down-regulation of p-JNK, and did not change p-P38 expression, while the protein level of p-ATF2 was decreased. Knockdown of PRCC expression led to activation of the JNK pathway, which promoted up-regulation of p-ATF2 (Fig. 6a, b). According to reports, ATF2 not only promotes tumor cell metastasis and maintains the characteristics of tumor stem cells through the JNK/ATF2 signaling pathway [15, 16], but also serves as an early response gene to stress and DNA damage [17,18,19]. ATF2 is a downstream factor of JNK and ATM/ATR signaling pathways, and performs cell response to external stimuli . Co-expression analysis showed that PRCC and ATM/ATR were negatively correlated (Fig. 5a). Western blot results also verified the same correlation (Fig. 6a).
Based on the above results, the molecular mechanism model of PRCC was deduced (Fig. 6c). In the absence of UV irradiation, the highly expressed PRCC inhibits the activation of ATF2 by inhibiting the JNK signaling pathway, therefore, the colony forming and metastasis abilities of HCC cells are inhibited. For normal cells, once cellular genomic DNA is damaged by UV, radiation, chemotherapeutics or other environmental factors, the JNK and ATM/ATR signaling pathways are activated, then prompting the phosphorylation of ATF2 protein. The activated ATF2 promotes cell apoptosis and DNA damage repair. But when PRCC is highly expressed, the JNK pathway is inhibited, the expression of ATM/ATR is down-regulated, and the expression of p-ATF2 is also down-regulated. At this time, if the genomic DNA of HCC cells is damaged, the HCC cells with high protein level of PRCC cannot respond as normal cells do, they neither directly enter the apoptotic process, nor stop cell cycle to complete DNA repairs. But they carry damaged DNA and mutations to continuously proliferate (Fig. 5c). This not only causes HCC cells to be resistant to radiotherapy and chemotherapeutics, but also causes HCC cells with numerous DNA mutations to become increasingly heterogeneous, which is extremely unfavorable for prognosis of patients.
High ectopic expression of PRCC leads to high ITH and short overall survival
MATH, generated from whole-exome sequencing (WES) of tumors and their matched normal DNA, was verified to be a simple, quantitative, and universally applicable method for the assessment of ITH . In order to prove the correlation between PRCC and ITH, as well as the relationship between ITH and overall survival of patients, SNV files and clinical data of 365 patients with liver cancer were downloaded from the TCGA database. The sample data of 14 cases were incomplete, and the sample data of 351 cases were actually analyzed. MATH was calculated through R language. The higher the MATH value, the higher the ITH. The patients with high expression of PRCC had higher MATH (or ITH), and the difference was statistically significant (P < 0.05) (Fig. 6d). The median value of MATH was used to distinguish the level of ITH. The survival analysis showed that high MATH (or ITH) corresponded to short overall survival (Fig. 6e). It could be concluded that the abnormally high expression of PRCC led to increased intratumoral heterogeneity in HCC patients, which in turn led to a shorter overall survival period for HCC patients.
The processes of tumor occurrence and development are always accompanied by specific changes in the genome, proteome, metabolome and epigenetics [21,22,23]. In recent years, although researchers have continued to reveal significant changes in molecules and their functions in a large number of cancers, there are still many unclear mechanisms for cancer metastasis, maintenance of cancer stem cells, and resistance to radiotherapy and chemotherapy. There is also a lack of effective diagnostic indicators, especially non-invasive diagnosis based on blood testing in clinic . This study investigated the role and mechanism of PRCC in HCC, for the purpose of elucidating its molecular function, regulatory mechanism and diagnostic value in HCC. The results showed that PRCC has high application potential as a substitute or adjuvant of AFP for clinical diagnosis and prognosis prediction of HCC patients.
However, molecular mechanism study found that PRCC overexpression could inhibit the metastasis and spheroidization of HCC cells. This phenomenon was verified in nude mice. Seemingly, it was inconsistent with the conclusion that the high expression of PRCC was related to poor prognosis of HCC. Through analysis of co-expression data in TCGA database, it was found that the expression of PRCC was significantly negatively correlated with the key factors involved in DNA damage repair process, such as ATM/ATR and HIPK2, and was significantly positively correlated with the G2/M cell cycle factors CDC25C and CDK1 (Fig. 6a). It was speculated that maybe PRCC indirectly leads to poor prognosis of HCC by affecting DNA damage repair pathways and cell cycle regulation. Our results bear out this conjecture.
As we know, in the classic signaling pathways of DNA damage repair and G2/M checkpoint, once cells are exposed to radiation or ultraviolet irradiation, cellular DNA will be broken and cross-linked, which will cause HIPK2, DNA-PK and ATM/ATR to activate and produce a series of responses [25,26,27]. On the one hand, cell apoptosis is induced through the HIPK2/P53 and ATM/ATR/P53 axis. On the other hand, the ATM/ATR/CHK1/CDC25/CDC2 axis blocks cells from G2 phase to M phase and completes DNA repair, or induces P53-independent cell apoptosis [28,29,30]. When PRCC is highly expressed, the expression of HIPK2, ATM and ATR proteins is down-regulated, and the expression of CDC25, PLK1, CDK7, etc. is up-regulated. At this time, the radiation- or ultraviolet radiation-induced DNA damage cannot initiate the downstream cell cycle arrest, DNA repair process or cell apoptosis through above molecules. While the increase of CDC25 and other proteins promotes the cell cycle process.
There are many factors that induce DNA mutations in the natural environment, such as ultraviolet radiation, ionizing radiation, some organic compounds, heavy metals, aspergillus flavus, various viruses, etc. [31,32,33,34]. The ability of cells to avoid carcinogenesis mainly depends on a sound DNA damage repair system . According to the results we obtained, the high expression of PRCC destroys the sensitivity of the repair system. Therefore, for HCC patients with high expression of PRCC, if radiotherapy or chemotherapy is used and induces DNA damage, it is likely that the treatment effect is not as good as that of patients with low expression of PRCC. Even if the patient does not receive radiotherapy and chemotherapy to induce DNA damage, the microenvironment containing viruses, inflammation factors, reactive oxygen species and aspergillus flavus, etc. will continue to induce DNA damage. The HCC patients with high PRCC expression are not sensitive to DNA damage. As aforementioned, cells carrying DNA damages and mutations will continue to proliferate and lead to an increased heterogeneity in HCC tissues.
Tumor heterogeneity possesses a huge challenge to biomarker prediction and treatment selection. This also means that the higher the heterogeneity of malignant tumors, the worse the prognosis of patients. Our study found that the high expression of PRCC enhances ITH and genomic instability. Although PRCC plays a certain role in inhibiting HCC cell metastasis, its high expression leads to the development and poor prognosis of HCC as a whole. The conclusion clearly explains the role of PRCC in the occurrence and development of HCC for the first time, and provides new clues for HCC diagnosis, treatment guidance, prognosis prediction and targeted therapy.
PRCC has high application potential as a substitute or adjuvant of AFP for clinical diagnosis of HCC. The high ectopic expression of PRCC not only causes HCC cells to resist to cell death induced by DNA damage, but also causes cancer cells with numerous DNA mutations to become increasingly heterogeneous, finally leading to a poor prognosis for HCC patients. These data suggested PRCC could be a promising therapeutic target in patients with HCC.
Availability of data and materials
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Enzyme linked immunosorbent assay
Mutant-allele tumor heterogeneity
Proline rich mitotic checkpoint control factor
Portal vein tumor thrombus
Receiver operating characteristic curve
Quantitative reverse transcription PCR
Single nucleotide variation
Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, et al. Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 2021;73:422–36.
Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci. 2019;76:4203–19.
Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237–47.
Liu Y, Liu L, Zhou Y, Zhou P, Yan Q, Chen X, et al. CKLF1 enhances inflammation-mediated carcinogenesis and prevents doxorubicin-induced apoptosis via IL6/STAT3 signaling in HCC. Clin Cancer Res. 2019;25:4141–54.
Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, et al. Incidence, clinicopathologic features, and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70:1089–97.
Agafonov DE, Deckert J, Wolf E, Odenwälder P, Bessonov S, Will CL, et al. Semiquantitative proteomic analysis of the human spliceosome via a novel two-dimensional gel electrophoresis method. Mol Cell Biol. 2011;31:2667–82.
Golas MM, Hartmuth K, Sander B, Kastner B, Deckert J, Dube P, et al. Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. EMBO J. 2007;26:1737–48.
Hegele A, Kamburov A, Grossmann A, Sourlis C, Wowro S, Weimann M, et al. Dynamic protein–protein interaction wiring of the human spliceosome. Mol Cell. 2012;45:567–80.
Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG. Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas. Proc Natl Acad Sci U S A. 2001;98:13808–13.
Ma D, Jiang Y, Liu X, Liu Y, Shao Z. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer Res Treat. 2017;162:39–48.
Gozdecka M, Lyons S, Kondo S, Taylor J, Li Y, Walczynski J, et al. JNK suppresses tumor formation via a gene-expression program mediated by ATF2. Cell Rep. 2014;9:1361–74.
Sharma GP, Gurung SK, Inam A, Nigam L, Bist A, Mohapatra D, et al. CID-6033590 inhibits p38MAPK pathway and induces S-phase cell cycle arrest and apoptosis in DU145 and PC-3 cells. Toxicol In Vitro. 2019;60:420–36.
Yan D, An G, Kuo MT. C-Jun N-terminal kinase signalling pathway in response to cisplatin. J Cell Mol Med. 2016;20:2013–9.
Lin J, Yu Y, Wang X, Ke Y, Sun C, Yue L, et al. Iguratimod inhibits the aggressiveness of rheumatoid fibroblast-like synoviocytes. J Immunol Res. 2019;2019:6929286.
Jin Y, Mao J, Wang H, Hou Z, Ma W, Zhang J, et al. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo. Biomed Pharmacother. 2013;67:337–45.
Tang J, Liao Y, He S, Shi J, Peng L, Xu X, et al. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling. J Transl Med. 2017;15:238.
Desai S, Kumar A, Laskar S, Pandey BN. Differential roles of ATF-2 in survival and DNA repair contributing to radioresistance induced by autocrine soluble factors in A549 lung cancer cells. Cell Signal. 2014;26:2424–35.
Bhoumik A, Ronai Z. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle. 2008;7:2341–5.
Liu Z, Gan L, Wu T, Feng F, Luo D, Gu H, et al. Adiponectin reduces ER stress-induced apoptosis through PPARα transcriptional regulation of ATF2 in mouse adipose. Cell Death Dis. 2016;7:e2487.
Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49:211–5.
Chakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-multi-omics approach: a new frontier in cancer research. Biomed Res Int. 2018;2018:9836256.
Crispo F, Condelli V, Lepore S, Notarangelo T, Sgambato A, Esposito F, et al. Metabolic dysregulations and epigenetics: a bidirectional interplay that drives tumor progression. Cells. 2019;8:798.
Cooper LA, Demicco EG, Saltz JH, Powell RT, Rao A, Lazar AJ. PanCancer insights from the cancer genome atlas: the pathologist’s perspective. J Pathol. 2018;244:512–24.
Yang JD, Liu MC, Kisiel JB. Circulating tumor DNA and hepatocellular carcinoma. Semin Liver Dis. 2019;39:452–62.
Ma M, Rodriguez A, Sugimoto K. Activation of ATR-related protein kinase upon DNA damage recognition. Curr Genet. 2020;66:327–33.
Matt S, Hofmann TG. The DNA damage-induced cell death response: a roadmap to kill cancer cells. Cell Mol Life Sci. 2016;73:2829–50.
Mohiuddin IS, Kang MH. DNA-PK as an emerging therapeutic target in carnce. Front Oncol. 2019;9:635.
Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, et al. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene. 2016;35:228–40.
Roos WP, Kaina B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 2013;332:237–48.
Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene. 2001;20:1803–15.
Ikehata H, Ono T. The mechanisms of UV mutagenesis. J Radiat Res. 2011;52:115–25.
Hirata A, Corcoran GB, Hirata F. Carcinogenic heavy metals, As3+ and Cr6+, increase affinity of nuclear mono-ubiquitinated annexin A1 for DNA containing 8-oxo-guanosine, and promote translesion DNA synthesis. Toxicol Appl Pharmacol. 2011;252:159–64.
Kowalska A, Walkiewicz K, Kozieł P, Muc-Wierzgoń M. Aflatoxins: characteristics and impact on human health. Postepy Hig Med Dosw (Online). 2017;71:315–27.
Gómez-Moreno A, Garaigorta U. Hepatitis B virus and DNA damage response: interactions and consequences for the infection. Viruses. 2017;9:304.
Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16:35–42.
Cerami E, Gao J, Dogrusoz U, Gross B, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: an Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2:401-404.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
We are grateful to Prof. Zhenxia Chen and Dr. Mengwei Shi from Huazhong Agricultural University for their kindly assistance and technical support in MATH calculation.
This work was supported by the National Key R&D Program of China (2018YFA0900902), and the National Natural Science Foundation of China (81702735 and 81773251).
Ethics approval and consent to participate
All HCC patients gave written informed consent on the use of clinical specimens for medical research. The relevant clinical sample collection and animal experiments for this study were approved by the Committee on Ethics of Medicine, Navy Military Medical University (Shanghai, China).
Consent for publication
All authors reviewed and approved the final manuscript. All authors supported publication of this manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1
: Figure S1. High expression of PRCC is associated with poor prognosis of HCC patients in TCGA database (http://www.cbioportal.org/). a. The high expression of PRCC is significantly negatively correlated with the overall survival of HCC patients (P < 0.05). b. The high expression of PRCC is not significantly correlated with the progression-free survival of HCC patients (P = 0.183). Figure S2. The effects of PRCC on the biological behavior of HCC cells. a. PRCC has no significant effect on the proliferation of HCC cells. b. PRCC inhibits the colony forming ability of HCC cells (*, P<0.05). c, d. PRCC inhibits the migration and invasion of HCC cells in vitro. The histograms are the quantitative analysis results (*, P < 0.05; **, P < 0.01; ***, P < 0.001). All data were representative of three independent experiments. Table S1. Primer sequences of RT-qPCR. Table S2. Antibody information.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, C., Lin, X., Sun, B. et al. PRCC reduces the sensitivity of cancer cells to DNA damage by inhibiting JNK and ATM/ATR pathways and results in a poor prognosis in hepatocellular carcinoma. Cell Biosci 11, 185 (2021). https://doi.org/10.1186/s13578-021-00699-x
- DNA damage
- Hepatocellular carcinoma
- JNK signaling pathway